Medical University of Graz

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)

  2026-525757-37-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Not yet recruiting

  A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)

  2026-525755-82-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Not yet recruiting

  A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)

  2025-522648-42-01· Phase 2/3· Crinetics Pharmaceuticals Inc.· Source

• Recruiting

  A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease

  2026-525197-19-00· Phase 2· Agomab Spain S.L.U.· Source

• Not yet recruiting

  CATCH AF - Atrial Fibrillation Detection in Cryptogenic Stroke

  NCT07899788· Medical University of Graz· Source

• Not yet recruiting

  A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body Weight

  NCT07845578· Phase 1· Novo Nordisk A/S· Source

• Recruiting

  Efanesoctocog alfa treatment in patients with congenital hemophilia A suffering from inflammation of joint lining

  2025-523896-44-00· Phase 3· GWT-Tud GmbH· Source

• Recruiting

  ABCSG R07 Rectal Cancer Registry

  NCT07780305· Austrian Breast & Colorectal Cancer Study Group· Source

• Recruiting

  Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

  NCT07711002· Phase 3· AstraZeneca· Source

• Not yet recruiting

  Rollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Benefited from Continued Treatment.

  2026-526419-13-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

  NCT07476729· Phase 3· Charite University, Berlin, Germany· Source

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

  NCT07737743· Phase 2· Novartis Pharmaceuticals· Source

• Not yet recruiting

  A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)

  NCT07760818· Phase 2· argenx· Source

• Recruiting

  Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

  NCT07626411· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT07711418· Phase 3· Nektar Therapeutics· Source

• Recruiting

  Early TRIPLE versus dual LIPID lowering treatment in peOple with atherosclerotic cardiovascular disease and hypercholesterolemia Undergoing elecTive revascularisation

  2026-525917-29-00· Phase 4· Medical University Of Graz· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

  NCT07481981· Phase 3· Insmed Incorporated· Source

• Recruiting

  Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

  NCT07621809· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

  NCT07318610· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  PHOENIX - ECP: Extracorporeal PHotopheresis for immune-related cOlitis and/or hEpatitis in advanced melaNoma with inadequate response to steroId eXposure

  2026-526261-14-00· Phase 2· Therakos Europe Limited· Source

• Recruiting

  Collagen Fingerprinting for Stratification of Pulmonary Hypertension (PH) Patients

  NCT07498244· Medical University of Graz· Source

• Recruiting

  Vessel Recoil in Specific CLTI Populations

  NCT07465627· Medical University of Graz· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

  NCT07581002· Phase 2/3· AbbVie· Source

• Not yet recruiting

  Cangrelor safety and pharmacodynamics in paediatric subjects with congenital heart disease

  2025-523109-14-00· Phase 3· Chiesi Farmaceutici S.p.A.· Source

• Recruiting

  BIO|MASTER.CorSky Family Post-market Study for the CorSky Family of ICDs

  NCT07360158· Biotronik SE & Co. KG· Source

• Recruiting

  A clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003)

  2025-524894-17-00· Phase 2/3· Eyebiotech Limited· Source

• Recruiting

  Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year

  2025-521590-13-00· Phase 3· Janssen Cilag International· Source

• Recruiting

  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)

  NCT07429266· Phase 3· Ono Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

  NCT07564414· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Research Study to Evaluate the Safety of NNC1679-0001 When Given to Healthy Participants and Participants With T2DM

  NCT07570992· Phase 1· Novo Nordisk A/S· Source

• Recruiting

  An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

  NCT07365332· Phase 3· Inhibikase Therapeutics· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

  NCT07225270· Phase 3· Genmab· Source

• Not yet recruiting

  Study of IMC-S118AI in Type 1 Diabetes

  NCT07493122· Phase 1· Immunocore Ltd· Source

• Not yet recruiting

  Digital Application for Stroke Health

  NCT07511868· VASCage GmbH· Source

• Recruiting

  EXERCISE AND THE IMMUNE RESPONSE IN LUNG CANCER

  NCT07267000· Medical University of Graz· Source

• Recruiting

  InRAD Observational Study

  NCT07213700· Stichting International Registry for Alzheimer's Disease and other Dementias Foundation· Source

• Enrolling by invitation

  A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma

  NCT07338968· Phase 3· Aura Biosciences· Source

• Recruiting

  Austrian PBC Registry

  NCT07598669· Medical University of Vienna· Source

• Recruiting

  Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07491445· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Incyte Corporation· Source

• Recruiting

  Two initial aflibercept 8 mg loading doses in treatment-naive neovascular AMD

  2025-523478-17-00· Phase 4· Medical University Of Graz· Source

• Recruiting

  Preeclampsia: Origin, Characteristics and Effects on Mother and Baby

  NCT07513558· Medical University of Graz· Source

• Recruiting

  Neoadjuvant Darovasertib in Primary Uveal Melanoma

  NCT07015190· Phase 3· IDEAYA Biosciences· Source

• Recruiting

  A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  NCT07216703· Phase 3· Merck Sharp & Dohme LLC· Source

Showing 50 of 271.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers19 recruiting
• Lung cancer10 recruiting
• Fatty liver disease (MASLD/MASH)7 recruiting
• High blood pressure7 recruiting
• Obesity7 recruiting
• Ovarian cancer7 recruiting
• Coronary artery disease6 recruiting
• Heart failure6 recruiting
• Stroke6 recruiting
• Colorectal cancer5 recruiting
• Crohn's disease5 recruiting
• Liver cirrhosis5 recruiting
• Macular degeneration5 recruiting
• Melanoma5 recruiting
• Myeloproliferative neoplasms5 recruiting
• Peripheral artery disease5 recruiting
• Prostate cancer5 recruiting
• Pulmonary arterial hypertension5 recruiting
• Amyloidosis4 recruiting
• Atrial fibrillation4 recruiting
• Metastatic breast cancer4 recruiting
• Sarcoma4 recruiting
• Sjögren's disease4 recruiting
• Type 2 diabetes4 recruiting
• Acute lymphoblastic leukaemia3 recruiting
• Acute myeloid leukaemia3 recruiting
• Aortic stenosis3 recruiting
• Bladder cancer3 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Endometrial cancer3 recruiting
• Hypertrophic cardiomyopathy3 recruiting
• Liver and biliary tract cancer3 recruiting
• Neuroendocrine tumours3 recruiting
• Parkinson disease3 recruiting
• Type 1 diabetes3 recruiting
• Ulcerative colitis3 recruiting
• Bronchiectasis2 recruiting
• Cervical cancer2 recruiting
• Chronic kidney disease2 recruiting
• COPD2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Follicular lymphoma2 recruiting
• Pancreatic cancer2 recruiting
• Psoriasis2 recruiting
• Alzheimer disease1 recruiting
• ANCA-associated vasculitis1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Congenital heart disease1 recruiting
• Cushing's syndrome1 recruiting
• Dystonia1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Glaucoma1 recruiting
• Glioblastoma1 recruiting
• Haemophilia1 recruiting
• Hidradenitis suppurativa1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Lupus (SLE)1 recruiting
• Multiple myeloma1 recruiting
• Myocarditis1 recruiting
• Neuroblastoma1 recruiting
• Primary biliary cholangitis1 recruiting
• Psoriatic arthritis1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Ventricular tachycardia1 recruiting
• Vitiligo1 recruiting

Closed trials

• Terminated

  AcoArt Litos PCB Below-the-knee Global Trial

  NCT06330493· Acotec Scientific Co., Ltd· Source

• Recruiting

  A Phase 2a Study of the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis

  2024-520201-39-00· Phase 2· Odyssey Therapeutics Inc.· Source

• Completed

  A single-center pilot study to establish a novel hypoglycemic clamp procedure to assess the time to spontaneous recovery from hypoglycemia in people with and without diabetes

  2025-520996-16-00· Phase 1/2· Medical University Of Graz· Source

• Completed

  A study to investigate efficacy and safety of SAR441566 in patients with ulcerative colitis

  NCT06867094· Phase 2· Sanofi-Aventis Recherche & Developpement· Source

• Completed

  A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia

  NCT06982846· Phase 1· Eli Lilly and Company· Source

• Active, not recruiting

  Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

  NCT06726265· Phase 3· Immutep S.A.S.· Source

• Completed

  A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome

  NCT06312020· Phase 2· Horizon Therapeutics Ireland Designated Activity Company· Source

• Completed

  A Research Study Comparing Different Ways of Increasing the Dose of NNC0519-0130 in Participants With Overweight or Obesity

  NCT06718998· Phase 1· Novo Nordisk A/S· Source

• Active, not recruiting

  A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

  NCT06422884· Phase 2· Endeavor Biomedicines, Inc.· Source

• Completed

  Two initial faricimab loading doses in treatment-naive neovascular AMD

  2024-514408-15-00· Phase 4· Medical University Of Graz· Source

• Active, not recruiting

  A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

  NCT06660173· Phase 2· Amgen· Source

• Completed

  Aflibercept 8mg for high-frequent Faricimab and prior Aflibercept 2mg treated Neovascular age-related macular degeneration: a monocenter, single-arm, open-label extension study (A-FAN)

  2024-515497-26-00· Phase 4· Medical University Of Graz· Source

• Active, not recruiting

  Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

  NCT05417789· Phase 3· SynOx Therapeutics Limited· Source

• Active, not recruiting

  A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

  NCT06525220· Phase 3· Genmab· Source

• Completed

  A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis

  2023-510249-79-00· Phase 2· Boehringer Ingelheim International GmbH· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Boehringer Ingelheim· Source

• Active, not recruiting

  Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

  NCT06211036· Phase 3· Amgen· Source

• Completed

  A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1

  NCT05870748· Phase 2· Sutro Biopharma Inc.· Source

• Completed

  Association of Ex Vivo Drug Response ( EVDR) and Clinical Outcome in Acute Myeloid Leukaemia (EXCYTE-2)

  NCT06648512· Exscientia AI Limited· Source

• Terminated

  Clock Proteins as Prognostic Markers

  NCT06302959· Medical University of Graz· Source

• Completed

  The Effect of Alcohol on Common Tremor Syndromes

  NCT06403280· Medical University of Graz· Source

• Completed

  A Study to Test How a New Long-acting Insulin Works in the Body of Patients With Type 2 Diabetes During Exercise and Prolonged Fasting

  NCT06288412· Phase 1· Novo Nordisk A/S· Source

• Active, not recruiting

  A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

  NCT06012435· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

  NCT06117774· Phase 3· Amgen· Source

• Completed

  Association Between Lifetime Physical Activity and Exercise and the Development of Wild-type Transthyretin Amyloid Cardiomyopathy

  NCT06261216· Medical University of Graz· Source

• Completed

  A Research Study Looking at How the Compound NNC0194-0499 Works With Birth Control Pills in Women Not Able to Bear Children.

  NCT06188026· Phase 1· Novo Nordisk A/S· Source

• Completed

  Mavacamten Impact on Myocardial Structure in Obstructive Hypertrophic Cardiomyopathy

  2022-502316-36-00· Phase 4· Myokardia Inc.· Source

• Completed

  A clinical trial to assess the safety and effects of AGMB-129 compared to placebo in patients with fibrostenotic Crohn’s disease.

  2022-502789-26-01· Phase 2· Agomab Spain S.L.U.· Source

• Recruiting

  DESTINY Breast Respond HER2-(Ultra)Low Europe

  NCT05945732· Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company· Source

• Completed

  A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)

  NCT05882877· Phase 3· Amgen Inc.· Source

• Active, not recruiting

  Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

  NCT05874401· Phase 4· Pharmacosmos A/S· Source

• Active, not recruiting

  A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight

  NCT06151964· Phase 1/2· AstraZeneca· Source

• Active, not recruiting

  Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

  NCT05911295· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Completed

  Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

  2022-502196-31-00· Phase 2/3· Kartos Therapeutics Inc.· Source

• Completed

  Clinical trial of MK-7648A in adults and children with skin cancer

  NCT05665595· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

  NCT05843578· Phase 2· Agomab Spain S.L.U.· Source

• Completed

  Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration

  NCT05941715· Phase 4· Medical University of Graz· Source

• Completed

  A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

  NCT05877547· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Tirbanibulin 1% Ointment for the Treatment of Chronically Sun-damaged Skin on the Face

  NCT05900258· Phase 4· Medical University of Graz· Source

• Active, not recruiting

  An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma

  2022-501463-40-01· Phase 3· Servier Affaires Medicales· Source

• Completed

  A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy

  NCT05582395· Phase 3· Myokardia Inc.· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

  NCT05803421· Phase 3· Eli Lilly and Company· Source

• Completed

  AT278, NovoRapid® and Humulin® R (U500) in Glucose Clamp Study

  NCT05754424· Phase 1· Arecor Limited· Source

• Completed

  A Study For Treatment Of Paroxysmal Atrial Fibrillation (PAF) With The THERMOCOOL SMARTTOUCH SF Catheter and TRUPULSE Generator

  NCT05752487· Biosense Webster, Inc.· Source

• Completed

  A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis

  NCT04781543· Phase 2· Horizon Therapeutics Ireland Designated Activity Company· Source

• Completed

  Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome

  NCT05737030· Phase 4· Medical University of Graz· Source

• Completed

  Interventional Platform Study Investigating the Impact of Digital Health Solutions on Health Outcomes and Health-Care Resource Utilization in Participants Receiving Systemic Treatment in Clinical Practice (ORIGAMA)

  2023-504342-55-00· Phase 2/3· F. Hoffmann-La Roche AG· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  BOLT Lithotripsy RESTORE ATK Trial

  NCT05662787· Bolt Medical· Source

Showing 50 of 136.

Conditions

Diseases this institution publishes on or runs trials for.

• Atrial fibrillation55 works · 10 trials
• Type 1 diabetes44 works · 10 trials
• Multiple sclerosis33 works · 1 trial
• Sarcoma21 works · 5 trials
• Bipolar disorder19 works · 0 trials
• Pulmonary arterial hypertension17 works · 10 trials
• Peripheral artery disease16 works · 12 trials
• Ventricular tachycardia15 works · 2 trials
• Amyloidosis14 works · 6 trials
• Liver cirrhosis12 works · 7 trials
• Hypertrophic cardiomyopathy12 works · 5 trials
• Sarcoidosis9 works · 0 trials
• Cerebral palsy8 works · 1 trial
• Multiple system atrophy7 works · 1 trial
• Dilated cardiomyopathy6 works · 0 trials
• Hidradenitis suppurativa6 works · 5 trials
• Mesothelioma5 works · 0 trials
• Essential tremor3 works · 2 trials